White Papers
The FDA’s Quality Management System Regulation (QMSR) changes more than terminology. This white paper breaks down the changes that go beyond a simple clause-mapping exercise, including retained FDA provisions and expanded access to internal quality records. It also outlines practical steps organizations can take to assess gaps, strengthen compliance, and prepare for FDA inspections under the new framework.
AI is becoming part of manufacturing and quality workflows, but its use needs clear controls. This white paper explains how life sciences organizations can define intended use, assess model credibility, maintain human oversight, and manage AI systems throughout their lifecycle.
FDA Computer Software Assurance gives life sciences organizations a risk-based approach to software validation that focuses resources on the systems and functions that matter most. This white paper examines the FDA’s CSA guidance, its relationship to traditional Computer System Validation, and practical steps for putting risk-based software assurance into practice.
Data integrity failures can create consequences far beyond the quality department. This white paper examines FDA enforcement trends, common data integrity gaps, audit trail review, computerized system controls, and practical steps pharmaceutical and biologics manufacturers can take to strengthen data governance and reduce compliance risk.
Supplier oversight is becoming increasingly complex for pharmaceutical, biotechnology, and other FDA-regulated organizations that rely on contract manufacturers, laboratories, and critical suppliers. Traditional supplier quality management practices, including periodic audits and questionnaires, may leave significant gaps between formal reviews as regulatory status, performance, and data integrity risks change.
FDA inspection readiness cannot be treated as a short-term preparation exercise before an expected inspection. For pharmaceutical, biotechnology, and medical device organizations, maintaining continuous inspection readiness means building a quality system that produces evidence of compliance during everyday operations, not just when an inspection is approaching.
An effective corrective and preventive action (CAPA) program should do more than document that an issue was addressed. It should demonstrate that the root cause was identified, the appropriate corrective action was implemented, and the fix actually worked. As regulatory scrutiny increases, organizations need CAPA processes built around evidence, meaningful effectiveness checks, and investigations that can withstand inspection.
